【参考文献】

    ［1］ 张之南. 血液病诊断及疗效标准［M］. 2版.北京:北京科学出版社,1998:33-36.

    ［2］ 何广胜，邵宗鸿，张益枝，等. 序贯强化免疫抑制并用造血生长因子治疗重型再生障碍性贫血［J］. 中华血液学杂志，2001，22(4):177-181.

    ［3］ DeMedeiros CR, Ribeiro RC, Bittencourt MA. Longterm outcome of 25 children and adolescents with severe aplastic anemia treated with antithymocyte globulin［J］. Braz J Med Biol Res, 2000,33(5):553-558.

    ［4］ Bacigalupo A，Bruno B，Saracco P，et al．Antilymphoeyteglobulin, cyclosporine， prednisolone， and granulocyte colonystimulating factor for severe aplastic anemia：an update of the GITMO／EBMT study on 100 patients［J］．Blood,2000,95：1931-1934.

    ［5］ Frickhofen N,Heimpel H,Kahwasser JP，et al．Antithymocyteglobulin with or without cyclosporin A：11 year followup of a randomized trial comparing treatments of aplastic anemia［J］.Blood,2003,101(4)：1236-1242.

    ［6］ Ahn MJ，Choi JH，Lee YY， et al. Outcome of adult severe or very severe aplastic anemia treated with immunosuppressive therapy compared with bone marrow transplantation: Multicenter trial［J］.Hematology,2003,78(2):133-138.

    ［7］ Robak E，Robak T，GoraTybor J，et al．Toxic epidermal necrolysis in a patient with severe aplastic anemia treated with cyclosporinA and GCSF［J］.J Med, 2001,32：31-39.

    ［8］ Tisdale JF, Maciejewski JP, Nunez O, et al． Late complications following treatment for severe aplastic anemia (SAA) with highdose cyclophosphamide (Cy): Followup of a randomized trial［J］.Blood,2002,100(13):4668-4670.